ALCEDIAG, a subsidiary of French diversified technologies firm ALCEN, welcomes Jean-Daniel Abraham as its new director of Research and Development.
D. Jean-Daniel Abraham will join the company in leading the research team developing IVD solutions for mental health conditions.
“I’m happy to join ALCEDIAG, who to me embodies the perfect collaboration and connection between Academia and Industry, allowing for the development of applicable solutions based on scientific discoveries”, said Jean-Daniel.
“I’m sure Dr. Abraham’s strong knowledge and experience in diagnostic for various pathologies will contribute to further advance the company’s roadmap”, added Dr. Dinah Weissmann, founder & CSO of ALCEDIAG.
Jean-Daniel Abraham holds a Ph.D. in Virology from the University of Strasbourg and an Engineering degree in Biology and Micro-Biology from the Polytech Marseille.
Dr. Abraham has a track record of decades of research in academic (INSERM, CNRS) and private laboratories (TRANSGENE, BIO-RAD), all of which he will harness to lead the R&D team at ALCEDIAG on its path to develop better diagnostics for mental health.